On 15 June 2026, Union Minister of State (Independent Charge) for Science & Technology Dr Jitendra Singh told a press conference at CSIR Headquarters, New Delhi that India's bioeconomy has grown nearly twenty-fold — from about USD 10 billion in 2014 to over USD 190 billion today — with a target of USD 300 billion by 2030. He placed it within a broader "12 years of science" story alongside the space-startup boom and improved weather forecasting. For CDS aspirants, the bioeconomy is an increasingly tested intersection of economy + science & technology + environment, and the BioE3 Policy is exactly the kind of named scheme examiners reward.
What Is the "Bioeconomy"?
The bioeconomy is the share of economic activity derived from biological resources and biotechnology — using living systems (cells, enzymes, microbes, plants) to make products and services. It spans:
- Biopharma & healthcare — vaccines, biosimilars, diagnostics, gene therapy.
- Bio-agriculture — improved seeds, biofertilisers, biopesticides.
- Bio-industrial — enzymes, biofuels, bioplastics, bio-based chemicals.
- Bio-IT/services — genomics, clinical research, bioinformatics.
India's strength was built early on low-cost vaccine manufacturing — it is often called the "pharmacy of the world" and the largest vaccine producer globally — a capability the COVID-19 vaccines (Covishield, Covaxin) showcased dramatically. That production base is why the bioeconomy could scale so fast, a theme worth linking to your general-science fundamentals.
The Headline Reform: the BioE3 Policy
The named driver Dr Jitendra Singh credits is the BioE3 Policy — "Biotechnology for Economy, Environment and Employment" — approved by the Union Cabinet in August 2024 and steered by the Department of Biotechnology (DBT) under the Ministry of Science & Technology. Its core ideas, ideal for an exam answer:
- Goal: foster high-performance biomanufacturing — making everyday products (chemicals, materials, foods, medicines) using biological routes instead of fossil-fuel-based or polluting ones.
- Six thematic sectors: bio-based chemicals & enzymes; smart proteins & functional foods; precision biotherapeutics; climate-resilient agriculture; carbon capture & utilisation; and marine & space biotechnology.
- The "3 E's": it explicitly ties biotech to Economy (growth/jobs), Environment (green, low-carbon production) and Employment — especially bio-manufacturing hubs in tier-2 and tier-3 cities.
- It supports Bio-AI hubs, biofoundries and aligns with the net-zero / LiFE (Lifestyle for Environment) vision.
In short, BioE3 reframes biotechnology not just as healthcare but as a green industrial strategy — the "next wave" after IT.
Why It Counts as Green Growth
The exam-friendly insight is that biomanufacturing can decarbonise industry: producing plastics, fuels and chemicals from microbes and biomass rather than petroleum cuts emissions and waste. That is why the bioeconomy doubles as a climate strategy and connects to India's net-zero-by-2070 pledge. It also advances Atmanirbhar Bharat — domestic biomanufacturing reduces import dependence in pharma ingredients and specialty chemicals — and creates skilled rural and small-town jobs, feeding directly into the growth and employment debates you track in the broader economy syllabus.
The Supporting Institutions and Missions
CDS questions often test the bodies behind a scheme, so map the biotech ecosystem:
- Department of Biotechnology (DBT) — the nodal department; its public-sector enterprise BIRAC funds biotech startups.
- Genome India Project — sequenced the genomes of thousands of Indians to build a reference database for precision medicine (a frequently asked "first").
- CSIR (Council of Scientific & Industrial Research) — the venue of this announcement, India's largest civilian R&D network.
- Earlier policy scaffolding includes the National Biotechnology Development Strategy and a fast-growing base of biotech startups (from a few hundred to thousands in a decade).
Note one nuance for accuracy: different official sources cite the 2024 bioeconomy at figures ranging from roughly $130 billion to over $165 billion; the minister's "over $190 billion today" reflects the latest 2026 estimate. What is consistent — and exam-safe — is the trajectory: ~$10 billion (2014) → multi-fold growth → $300 billion target by 2030.
Why India Could Scale So Fast: The Pharma Backbone
The bioeconomy did not grow from nothing — it stands on India's formidable pharmaceutical and vaccine base. India supplies a large share of the world's generic medicines and is the largest vaccine manufacturer globally; the Serum Institute of India alone is the world's biggest vaccine maker by volume. During the COVID-19 pandemic, India produced Covishield and the indigenous Covaxin at scale and ran one of the largest vaccination drives in history through the CoWIN platform — proof of both manufacturing depth and digital delivery. Programmes like Pradhan Mantri Bhartiya Janaushadhi Pariyojana (Jan Aushadhi), which sells affordable generic medicines, extend this strength to public health at home. This existing capability in affordable, high-volume biomanufacturing is precisely why India can credibly target a $300-billion bioeconomy — it is scaling a proven base into new areas like biosimilars, gene therapy, biofuels and bio-based materials.
The Wider "12-Year Science" Story
Dr Jitendra Singh framed the bioeconomy within a broader transformation of Indian science that CDS aspirants should be able to summarise. He cited the space economy rising on the back of 400-plus space startups (projected to grow from about $8 billion to $45 billion), and a leap in weather forecasting capability — the network of Doppler weather radars expanding from 17 to about 50, with another 50 planned — which sharpens cyclone and monsoon prediction that directly protects farmers and coastal communities. The common thread is a deliberate push to move science "from the laboratory to the lives of citizens" through a whole-of-government approach, backing startups, inviting private participation and funding frontier research. For an exam answer, the bioeconomy is best presented as one pillar of this larger story — biotechnology, space and earth sciences together forming the technological engine of the Viksit Bharat 2047 vision, with measurable economic and welfare payoffs rather than abstract ambition.
The Startup Engine and the Energy Link
A crucial enabler behind the numbers is the biotech startup ecosystem. Through BIRAC (Biotechnology Industry Research Assistance Council), a not-for-profit enterprise of the Department of Biotechnology, the government has seeded thousands of biotech startups and incubators — the count has climbed from a few hundred a decade ago to several thousand today. These young firms work on everything from low-cost diagnostics and biosimilars to agricultural microbes and lab-grown proteins, spreading high-skill jobs well beyond the metros. The bioeconomy also intersects directly with India's energy transition: the push for ethanol blending in petrol (India achieved its 20% blending ambition ahead of schedule) and for compressed biogas under the SATAT scheme turns agricultural waste into fuel, cutting both crude imports and stubble-burning pollution. Seen this way, biotechnology is not a niche sector but a connective tissue running through healthcare, agriculture, energy and climate policy — which is precisely why the government treats the bioeconomy as a strategic priority and why it has become fertile ground for CDS questions that reward candidates who can link these themes together.
🎯 Practice MCQs
Q1. The BioE3 Policy's three "E's" stand for: (a) Energy, Environment, Equity (b) Economy, Environment, Employment (c) Education, Economy, Energy (d) Environment, Equity, Employment → (b).
Q2. The BioE3 Policy is implemented by which department? (a) DPIIT (b) Department of Science & Technology (c) Department of Biotechnology (DBT) (d) NITI Aayog → (c) — approved in August 2024.
Q3. India's bioeconomy is targeted to reach what value by 2030? (a) USD 100 billion (b) USD 190 billion (c) USD 300 billion (d) USD 500 billion → (c).
Q4. India is often called the "pharmacy of the world" mainly because it is the world's: (a) Largest exporter of crude drugs only (b) Largest producer of vaccines and a major generics maker (c) Only maker of mRNA vaccines (d) Largest importer of medicines → (b).
Q5. Which of the following is not a thematic sector under BioE3? (a) Smart proteins & functional foods (b) Precision biotherapeutics (c) Carbon capture & utilisation (d) Semiconductor fabrication → (d) — semiconductors are outside biotech.
Q6. The Genome India Project is associated with: (a) Mapping India's groundwater (b) Sequencing the genomes of Indians for a reference database (c) A satellite navigation system (d) A crop-insurance scheme → (b).
📋 How this gets asked (PYQ pattern)
CDS/OTA economy and science questions reliably test named policies (BioE3) and their nodal department, the bioeconomy growth/target figures, India as the "pharmacy of the world"/largest vaccine maker, and BIRAC/Genome India as the institutional backbone. The fresh, this-cycle hooks: the $190-billion bioeconomy and the $300-billion-by-2030 target. Expect "which ministry/department runs X" and statement-based items.
Biotech and the green economy are rising CDS themes. Stay current at CDS/OTA Current Affairs and strengthen your prep with Cavalier's upcoming CDS courses.
✍️ Written by Aditya Tiwari — CDS/OTA General Studies and science-&-economy faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk. The Cavalier has trained NDA/CDS/SSB aspirants since 2001 (Facebook · YouTube).
Source: Ministry of Science & Technology PIB release, 15 June 2026 (PRID 2273071). BioE3 Policy details and bioeconomy figures cross-verified against the Department of Biotechnology and PIB references.